BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26209901)

  • 21. Targeting of eosinophils in asthma.
    Molfino NA
    Expert Opin Biol Ther; 2012 Jul; 12(7):807-9. PubMed ID: 22500988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
    Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
    N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
    [No Abstract]   [Full Text] [Related]  

  • 23. An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes.
    Chen MM; Roufosse F; Wang SA; Verstovsek S; Durrani SR; Rothenberg ME; Pongdee T; Butterfield J; Lax T; Wechsler ME; Stein ML; Ogbogu PU; Kahwash BM; Mathur SK; Simon D; Akuthota P; Holland N; Wetzler L; Ware JM; Guo C; Fay MP; Khoury P; Klion AD; Bochner BS
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1217-1228.e3. PubMed ID: 35181548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
    Shrimanker R; Pavord ID
    BioDrugs; 2017 Apr; 31(2):93-103. PubMed ID: 28364396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
    Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
    N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary eosinophilic lung diseases.
    Rose DM; Hrncir DE
    Allergy Asthma Proc; 2013; 34(1):19-25. PubMed ID: 23406932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
    Barnes PJ
    J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.
    Klion A
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):326-331. PubMed ID: 30504328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma.
    de Groot JC; van Roon EN; Storm H; Veeger NJ; Zwinderman AH; Hiemstra PS; Bel EH; ten Brinke A
    J Allergy Clin Immunol; 2015 Mar; 135(3):670-5.e3. PubMed ID: 25617224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophil apoptosis as a therapeutic target in allergic asthma.
    Ilmarinen P; Kankaanranta H
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):109-17. PubMed ID: 24148899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
    Chung KF
    J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Biotherapies for the treatment of asthma: are they the treatment of the future?].
    Tonnel AB; Denis G; Lelong J
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S44-10S48. PubMed ID: 17127963
    [No Abstract]   [Full Text] [Related]  

  • 33. Hypereosinophilic syndrome associated with occlusive coronary thrombosis and right ventricular thrombus.
    Sato Y; Fukunaga T; Hayashi T; Asada Y
    Pathol Int; 2008 Feb; 58(2):138-41. PubMed ID: 18199165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel targeted therapies for eosinophil-associated diseases and allergy.
    Radonjic-Hoesli S; Valent P; Klion AD; Wechsler ME; Simon HU
    Annu Rev Pharmacol Toxicol; 2015; 55():633-56. PubMed ID: 25340931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-interleukin-5 antibody therapy in asthma and allergies.
    Corren J
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
    Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
    J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The idiopathic hypereosinophilic syndrome.
    Lin DA; Boyce JA
    Allergy Asthma Proc; 2003; 24(6):417-20. PubMed ID: 14763243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The targeted eosinophil-lowering effects of dexpramipexole in clinical studies.
    Dworetzky SI; Hebrank GT; Archibald DG; Reynolds IJ; Farwell W; Bozik ME
    Blood Cells Mol Dis; 2017 Mar; 63():62-65. PubMed ID: 28178599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combating the eosinophil with anti-interleukin-5 therapy.
    Wechsler ME
    N Engl J Med; 2008 Mar; 358(12):1293-4. PubMed ID: 18344569
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.